97 F.4th 915
Fed. Cir.2024Background
- Janssen Pharmaceuticals sued Teva Pharmaceuticals for infringing U.S. Patent No. 9,439,906, which relates to dosing regimens for paliperidone palmitate, a schizophrenia treatment.
- Teva stipulated to infringement but contested validity, arguing the asserted claims were obvious and, for some claims, indefinite.
- The district court found for Janssen, concluding Teva failed to prove invalidity on either basis; Teva appealed.
- The central dispute was whether the patented dosing regimens (specifically for initial and maintenance dosing in certain patient populations) were non-obvious over prior art disclosing similar regimens and formulations.
- The prior art included a Phase III clinical trial protocol (the ’548 protocol), an earlier patent on paliperidone palmitate formulations (the ’544 patent), and an international publication on paliperidone palmitate (WO’384).
- The Federal Circuit reviewed the district court’s nonobviousness and indefiniteness rulings.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether the court added unclaimed limitations in obviousness analysis (population-wide and mild impairment requirements) | Claims do not require population-wide dosing or limitation to mild renal impairment. | Prior art did not show regimen was safe or effective for entire population / all impairment levels. | District court erred by requiring these unclaimed limitations; remand necessary. |
| Whether the obviousness analysis was too rigid under KSR | Prior art must expressly disclose each claim element; focus on claimed invention only. | POSA would understand to combine prior art using ordinary creativity. | District court used an impermissibly rigid approach; remand for proper evaluation. |
| Whether secondary considerations (e.g., unexpected results, praise, commercial success) preclude obviousness | Secondary considerations favor nonobviousness and are linked to claimed invention. | No proper nexus or significance; blocking patents impact weight; flawed comparison of results. | District court must reassess secondary considerations/nexus on remand. |
| Whether particle-size claims are indefinite due to ambiguity in measurement methods | Measurement techniques are standard or at least commonly understood in the art. | Variation in methods yields different results; fails definiteness requirement. | No clear error in district court’s factual finding; affirmed as not indefinite. |
Key Cases Cited
- KSR Int’l Co. v. Teleflex Inc., 550 U.S. 398 (Flexible standard for obviousness; no need for precise prior art teaching.)
- Nautilus, Inc. v. Biosig Instruments, Inc., 572 U.S. 898 (Definiteness requires that claims inform with reasonable certainty.)
- PAR Pharm., Inc. v. TWI Pharms., Inc., 773 F.3d 1186 (Remand appropriate when district court applies incorrect obviousness standard.)
- Galderma Labs., L.P. v. Tolmar, Inc., 737 F.3d 731 (Teaching away requires actual criticism or discouragement in prior art.)
- Bristol-Myers Squibb Co. v. Teva Pharms. USA, Inc., 752 F.3d 967 (Unexpected results analysis requires comparison to closest prior art.)